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esponsibility of Xi0Abstract A simple and selective ultra performance liquid chromatography–electrospray ionization
tandem mass spectrometry (UPLC–ESI-MS/MS) assay was developed for the determination of the human
plasma protein binding of four bioactive ﬂavonoids (such as orientin and vitexin) in Polygonum orientale.
Protein precipitation was used for sample preparation. Equilibrium dialysis technique was applied to
determine the plasma protein binding under physiological conditions. The separation was achieved
through a Waters C18 column with a mobile phase composed of 0.1% formic acid in acetonitrile and 0.1%
aqueous formic acid using step gradient elution at a ﬂow rate of 0.35 mL/min. A Waters ACQUITY™
TQD system was operated under the multiple reaction monitoring (MRM) mode of positive electrospray
ionization. All of the recovery, precision, accuracy and stability of the method met the requirements. Good
correlations (r40.99) of the four compounds were found, which suggested that these compounds can be
simultaneously determined with acceptable accuracy. Results showed that the plasma protein bindings of
the four bioactive ﬂavonoids were in the range of 74–89% over the six concentrations studied. The
binding parameters containing protein binding afﬁnity, protein binding dissociation constant, and protein
binding site were studied. The maximum ability to bind with protein was also determined in the assay in
order to understand the drug-protein binding of each compound better.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Else
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an Jiaotong University.1. Introduction
Plasma-protein binding strongly affects the pharmacokinetic beha-
vior of drugs with consequences in their overall pharmacological
action [1]. The binding degree of a drug towards plasma proteins
plays an important role in its distribution, elimination, and
pharmacological effect.vier B.V. All rights reserved.
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cines, has been widely used for the remedy of rheumatic arthritis,
coronary disease, and hernia in Miao's medicine. Modern pharma-
cological studies showed that the aqueous extract of P. orientale
possessed anti-myocardial ischemia and antioxidation activity
[2,3]. Chemical investigations have shown that among the
ﬂavonoids, lignans and saponins [4,5] present as the major
constituents in this herb, ﬂavonoids are believed to be the active
components in P. orientale [6]. Orientin, vitexin, cynaroside, and
quercitrin (Fig. 1) are the main active constituents of P. orientale
and can be considered as the marker compounds for the quality
evaluation or standardization of P. orientale [7].
Since the non-speciﬁc binding of a drug to plasma proteins
modulates the availability of the drug to its intended target and the
free fractions of a drug exert the main therapeutic effects occurring
throughout the body, plasma protein binding is crucial for
evaluating the extent and duration of the therapeutic action of a
drug. Plasma protein binding data are therefore very useful in the
design of optimal dose regimens and estimation of safety margins.
As orientin, vitexin, cynaroside and quercitrin are the major active
components of P. orientale and its several compound preparations
have been under clinical evaluation [8], it is essential to develop a
method to determine their plasma protein binding. Currently, many
investigations [9,10] have been conducted on the quantitative
analysis of orientin, vitexin, cynaroside and quercitrin in the plant
material and pharmaceutical preparations or biological ﬂuids using
High Performance Liquid Chromatography–Ultra Violet (HPLC–
UV) and/or HPLC–MS/MS. However, as we know, there are still
no reports about the interaction of these ﬂavonoids and humanOrientin Vitexin
Cynaroside Quercitrin
Puerarin
Fig. 1 Chemical structures of orientin, vitexin, cynaroside, quercitrin
and puerarin (I.S.).proteins. In this investigation, a simple selective, and reliable
UPLC–ESI-MS/MS assay that signiﬁcantly reduced the matrix
effects had been developed for the determination of the human
plasma protein binding of four bioactive ﬂavonoids (i.e., orientin,
vitexin, cynaroside and quercitrin) in P. orientale.2. Experimental
2.1. Materials and reagents
The reference standards of orientin, vitexin, cynaroside and
quercitrin were isolated from P. orientale in our laboratory and
their structures were conﬁrmed by comparison of their MS, nuclear
magnetic resonance (NMR) and speciﬁc rotation data with those
reported in the literature. Their purities were all over 98% as
determined by HPLC. The internal standard (I.S.) puerarin (≥ 99%
purity) was purchased from National Institute for the Control of
Pharmaceuticals and Biological Products (Beijing, China). Acet-
onitrile was of HPLC-grade from Merck Company (Darmstadt,
Germany). HPLC-grade methanol was purchased from Tianjin
Kermel Chemical Reagents Development Centre (Tianjin, China).
All other reagents were of analytical grade.
Semi-permeable membranes with a molecular cut-off of 10 kDa
were obtained from Solarbio Biological Product Company (Beij-
ing, China). The membranes were ﬁrst washed with distilled water,
and then soaked in phosphate buffer (pH¼7.4) before being
placed into the plasma for analysis. The human blood was offered
by the blood centre of Guizhou Province (licensing agreement:
07001).2.2. Chromatography
LC analyses were performed on a Waters ACQUITY™ UPLC
with the power of UPLC (Waters, Milford, MA, USA). Chromato-
graphic separation was achieved on a Waters BEH C18 column
(2.1 mm 50 mm, 1.7 mm, Waters, Milford, MA, USA) and a C18
-guard column Waters Van Guard BEH (2.1 mm 5 mm, 1.7 mm,
Waters, Milford, MA, USA) with a step gradient of 0.1% formic
acid in acetonitrile (A) and 0.1% aqueous formic acid (B)
[0–0.5 min, A (10%); 0.5–2 min, A (10–30%); 2–2.5 min, A
(90%); 2.5–3.5 min, A (10%)] at a ﬂow rate of 0.35 mL/min.
The column was maintained at 45 1C, the auto-sampler was at
15 1C and the injection volume was 1 mL.2.3. Mass spectrometry
All the mass experiments were carried out using a Waters
ACQUITY TQD (triple quadrupole mass spectrometer) equipped
with a Z-spray ESI source. The cone voltage was set at 3 kV.
Nitrogen was used as nebulizing gas with a source temperature of
120 1C. Desolvation gas (nitrogen) was heated to 350 1C and
delivered at a ﬂow rate of 650 L/h. Argon was used as collision
gas at a ﬂow rate of 0.16 mL/min. All the data were collected by
the MassLynx™ V4.1 workstation (Micromass, Manchester, UK).
Quantiﬁcation was performed using positive MRM mode with m/z
449.2-329.2 for orientin, m/z 433.2-313.0 for vitexin, m/z
449.2-287.1 for cynaroside, m/z 449.2-303.4 for quercitrin,
and m/z 417.0-267.0 for puerarin. The cone voltages for orientin,
vitexin, cynaroside, quercitrin and puerarin were 35, 35, 35, 35,
Y. Huang et al.378and 30 V, respectively. The optimized collision energies of 30, 30,
25, 30, and 15 eV were used for these components.
2.4. Preparation of standard solutions and quality control
samples
Stock solutions of standards were prepared by dissolving orientin,
vitexin, cynaroside and quercitrin in methanol to yield their
concentrations of 1.006, 0.996, 0.982, 1.010 mg/mL, respectively.
Working standard solutions were freshly prepared by mixing and
diluting the standard solution with methanol to give six concen-
trations in the plasma and phosphate buffer. The concentration of
puerarin (I.S., 9 mg/mL) was made through the diluting in
methanol for use. All the solutions were stored at −20 1C and
warmed to the room temperature before use.
To prepare the standard calibration samples, the mixed standard
solutions for six concentrations (50 mL) were spiked into the blank
plasmas (200 mL) or phosphate buffer (1 mL). The samples were
then treated as the following sample preparation procedure. The
quality control (QC) samples, which were used in the validation,
were prepared in the same way as the standard calibration samples.
2.5. Sample preparation
2.5.1. Preparation of the extract of P. orientale
The dried P. orientale was extracted three times by reﬂuxing with
boiling water (1:10, w/v) for 1 h, and the extraction solutions were
combined to be ﬁltered, concentrated under reduced pressure and
then precipitated with ethanol. The ethanol was removed under
reduced pressure with discarding of precipitate. The concentration
of 1 g/mL of extract was produced by dissolving residue in water
then extracted with n-butanol (2:1, v/v) for four times. The n-
butanol was removed under reduced pressure, and the residue was
dissolved with 80% ethanol, and then loaded on the polyamide
column, elution with 80% ethanol will be proceeded. Therefore,
the extract of P. orientale was attained under reduced pressure to
dryness.
2.5.2. The plasma samples (ﬂuid within the dialysis bags)
To 200 mL of plasma, 50 mL of methanol, 20 mL of the IS solution
(9 mg/mL), and 50 mL of formic acid (3 M) were added. The
mixture was vortex-mixed for 1 min. Addition of 800 mL of
methanol to the mixture followed by vortex-mixing (1 min) and
sonication (5 min) gave a suspension, centrifugation (36,670 g,
10 min, 4 1C) of which allowed the precipitation of the proteins.
The upper organic phase was transferred into clean tubes.
The process of evaporation of all the upper samples under a
gentle stream of nitrogen at 48 1C gave rise to a series of residues,
each of which was redissolved in 500 mL of methanol. The mixture
was then vortex-mixed (1 min), sonicated (5 min), and centrifuged
(36,670g, 10 min, 4 1C). 1 mL of the supernatant was injected into
the UPLC–MS/MS system for analysis.
2.5.3. The phosphate buffer samples (ﬂuid outside the dialysis
bags)
Unlike the plasma samples, the phosphate buffer samples do not
require the step of precipitation the proteins. The method was
specially established to the samples.
To 1 mL of phosphate buffer, 50 mL of methanol, 20 mL of the
I.S. solution (9 mg/mL) and 50 mL of formic acid (3 M) were
added and the mixture was vortex-mixed for 1 min. All othersample processing (except for precipitation of the proteins) were
the same as those in Section 2.5.1.2.6. Method validation
Because of the matrix effects in the detection with LC–ESI-MS/MS,
two different media (i.e., human plasma and phosphate buffer)
involved in this report had been distributed with the differently
quantitative methods which will be veriﬁed using different method
validations [11,12]. For the large distance of concentrations between
the ﬂuid inside and outside the dialysis bags, the errors would rose
when the analytes have been quantitated with the same calibration
curves; while when the mode of electrospray ionization was used,
the different media may affect the MS signal [13]. With the
separated methods that were described in this paper, these effects
could be avoided.2.6.1. Selectivity
The speciﬁcity of the method was determined by comparing the
chromatograms of blank plasma or phosphate buffer with the
corresponding spiked plasma or phosphate buffer. Blank samples
of all matrixes were extracted to certify the absence of
interfering peaks.2.6.2. Linearity of calibration and the lower limit of detection
(LLOD)
Calibration curves were constructed by performing a linear
regression analysis of the peak area ratios (y) of each compound
to the internal standard vs. their respective concentrations (x) by
the 1/x2 weighted least-square linear regression. The LLOD was
the concentration of a compound that produced a signal three times
the analytical background noise.2.6.3. Precision, accuracy and recovery
The intra- and inter-day precisions were obtained by analyzing the
QC samples of orientin, vitexin, cynaroside and quercitrin at three
levels in six replicates within one day and for three consecutive
days. The accuracy was determined as the percentage difference
between the mean detected concentrations and the nominal
concentrations. The recovery of each compound was assessed by
comparing the peak height of a sample containing a known
amount of a compound with the peak height obtained from direct
injections of a standard solution containing the same concentration
of the compound.2.6.4. Analyte stability
The stability of the four analytes in human plasma and phosphate
buffer was evaluated at three concentration levels of processed QC
samples and in three replicates. The samples were either stored for
6 h at ambient temperature or freeze (−20 1C)–thaw (room
temperature) for three times before being stored under auto-
sampler conditions (15 1C) for 24 h. Stability was assessed by
comparing the mean concentration of the stored QC samples with
the mean concentration of freshly prepared QC samples.
The stability of the drug in human plasma and phosphate buffer
was also evaluated. The samples were stored for 96 h at 4 1C.
Stability was assessed by comparing the same concentration of the
drug which is prepared freshly.
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The extract was made the concentrations of 1.2, 3, 6, 15, 30,
60 mg/mL by dissolving the extracts from P. orientale in the
phosphate buffer. The blank human plasma was added into the
semi-permeable membrane. The dialysis bag was placed in a ﬂask
containing a volume of phosphate buffer. In prior to analysis, the
dialysis system was incubated at 4 1C for 72 h to achieve
equilibrium between plasma and phosphate buffer. The ﬂuid
outside and inside the dialysis bags was collected after the
incubation. Concentrations within the dialysis bags which contain
the compounds as protein-bound residues and in free form were
determined as the total compound concentration, the concentra-
tions of ﬂuid outside the dialysis bags were determined as the
concentrations of free form.
The binding degrees of the four compounds in the equilibrium
dialysis experiments can be expressed as
Fuð%Þ ¼
Dt−Df
Dt
100%
where Dt is the total compound concentration in the plasma
compartment and Df is the concentration of the compound in free
form in the phosphate buffer compartment.3. Results and discussion
3.1. Selectivity
Typical chromatograms of blank samples, spiked samples, plasma
and phosphate buffer containing extract of P. orientale in the
drug–protein binding study are shown in Fig. 2. The results
showed that the four ﬂavonoids and the internal standard were wellFig. 2 UPLC chromatograms of plasma and phosphate buffer solution
plasma; (B) blank buffer solution; (C) the plasma sample; and (D) the phseparated and no signiﬁcant interferences were observed at the
retention times of the analytes and the internal standard.3.2. Linearity of calibration and LLOD
Under current chromatographic conditions, all the four compounds
performed good linearity (r40.996). The ranges of the calibration
curves were speciﬁed as approximately 80–120% of the test
concentration of the samples. These ranges covered the amounts
of the analytes of all samples and provided suitable levels of
linearity, accuracy and precision. The results are listed in Table 1.3.3. Precision, accuracy and extraction recovery
The data of intra- and inter-day precisions, accuracy and recovery
for these analytes in the two media from the QC samples (Table 2)
showed that the intra- and inter-day precisions (RSDs) were less
than 12.1% and 14.1%, and the accuracy was within 113.7%,
while the mean recoveries of the four analytes at three different
concentrations were ranged from 81.8% to 108.4% in plasma and
82.3%–104.1% in phosphate buffer.3.4. Analyte stability
The stability of orientin, vitexin, cynaroside and quercitrin during
sample processing and of the QC samples were investigated.
The results showed that the four analytes were stable for at least 6 h
at ambient temperatures in QC samples and 24 h in auto-sampler
conditions. While in QC samples, three freeze–thaw cycles showed a
reduction of the concentration below change of 10%.with puerarin, orientin, vitexin, cynaroside and quercitrin. (A) Blank
osphate buffer solution sample.
Table 1 Linear relation between peak area and concentration in the two media.
Media Analyte Regression equation r Linear range (mg/mL) LLOD (mg/mL)
Plasma Orientin y¼0.472 x0.027 0.998 0.330–80.2 0.0146
Vitexin y¼0.651 x0.030 0.999 0.108–26.2 0.0023
Cynaroside y¼2.76 x0.013 0.998 0.0152–3.68 0.0018
Quercitrin y¼0.538 x0.044 0.997 0.0831–20.2 0.036
Phosphate buffer Orientin y¼2.84 x0.059 0.998 0.0274–6.01 0.0028
Vitexin y¼3.46 x0.066 0.998 0.0246–5.98 0.0105
Cynaroside y¼130.5 x0.025 0.997 0.00303–0.737 0.0006
Quercitrin y¼2.67 x0.027 0.996 0.0104–2.53 0.0051
Table 2 Summary of precision, accuracy and recovery from QC samples (n¼3 days and six replicates per day).
Media Analyte Added conc.
(mg/mL)
Found conc.
(mg/mL)
Precision Accuracy (%) Extraction recovery (%)
Intra-day
(RSD, %)
Inter-day
(RSD, %)
Plasma Orientin 0.99 0.9370.07 3.6 3.5 94.0 100.0
8.91 9.8070.45 3.4 3.0 110.0 106.5
80.16 86.0171.01 3.6 5.5 107.3 106.7
Vitexin 0.32 0.2770.03 4.2 2.4 82.7 81.8
2.91 2.8170.17 5.8 1.1 96.9 103.1
26.15 30.4070.34 3.3 3.6 112.7 103.8
Cynaroside 0.045 0.04170.005 8.0 4.5 91.1 98.0
0.41 0.4070.02 5.3 1.9 98.0 103.2
3.68 3.9470.10 2.5 4.5 106.5 106.0
Quercitrin 0.25 0.2470.01 4.8 5.4 94.9 106.6
2.24 1.9370.10 4.6 7.5 86.1 108.4
20.20 22.1970.43 2.2 8.3 110.3 100.8
Posphate buffer Orientin 0.074 0.06770.004 5.4 4.8 90.3 83.7
0.67 0.6370.04 7.0 7.6 94.7 91.7
6.01 6.5870.20 3.0 3.6 109.5 99.2
Vitexin 0.074 0.06970.004 5.9 4.5 93.0 82.3
0.66 0.6470.03 4.0 7.1 96.6 89.7
5.98 7.1370.17 2.4 3.1 109.3 104.1
Cynaroside 0.009 0.00770.001 12.1 14.1 82.2 92.2
0.082 0.08370.007 8.4 7.0 101.0 91.7
0.74 0.8570.03 3.9 3.4 113.7 98.6
Quercitrin 0.031 0.02570.002 7.5 5.8 80.7 85.9
0.28 0.2470.03 10.4 4.9 85.6 93.3
2.53 2.4770.07 2.9 7.2 97.9 84.9
Y. Huang et al.380The results of the analytes from the drug showed that the drug
was stabilized in plasma and phosphate buffer samples at least
96 h within the reduce of 3%.
3.5. Plasma protein binding
Because the free and bound amounts of the drug are not affected in
the experiment, equilibrium dialysis has been widely used for
protein binding measurements. This technique has been success-
fully applied to quantify the concentration of each compound in
human plasma in the present compound–protein binding study.
The binding degree of each compound to the human plasma isshown in Fig. 3. The results showed that the binding degrees of
orientin, vitexin, cynaroside and quercitrin were in the range of
74–89% covering all concentrations studied.
For better understanding of the binding of these analytes to
plasma proteins, the plasma protein binding afﬁnity (K) and
dissociation constant (Kdp), the number of binding sites (n), and
the maximum binding ability (β) of these compounds were derived
based on the modiﬁed Scatchard equation. These parameters could
be expressed as follows [14,15]:
r
Df
¼ nK−rK
Table 3 Plasma protein binding parameters of the four
bioactive compounds in the drug–protein binding.
Analyte K 104
(L/mol)
n
( 10−4)
β
(μmol/g)
Kdp
(μmol/L)
Orientin 3.973 9.659 2.685 26.55
Vitexin 5.825 5.128 1.650 19.72
Cynaroside 22.90 0.9820 0.3660 5.512
Quercitrin 19.11 2.285 0.6420 5.288
The concentrations of the extract of P. orientale were ranged from
1.2 to 60 μg/mL.
Fig. 3 The protein binding of orientin, vitexin, cynaroside and
quercitrin in the extract of P. orientale as determined in human
plasma.
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Pt  Df
Df þ Dt−Df W
−Kdp
where r is calculated as [Db]/[Pt], Df, Db, and Dt are expressed
as the free, bound, and total-drug concentration, respectively;
Pt (71.28 g/L) is the total protein in human plasma which
is calculated by the Lowry method; W is the plasma water content
(99.25%). The concrete results are presented in Table 3. After
calculation of Kdp and β, the compound–protein binding in any
concentration can be calculated by the following equation:
Fuð%Þ ¼ 1= W þ
Pt  β
Df þ Kdp
 4. Conclusions
A sensitive, accurate and precise method based on equilibrium
dialysis and UPLC–ESI-MS/MS has been developed and validated
for simultaneous determination of the binding degrees of orientin,
vitexin, cynaroside, and quercitrin in P. orientale within 3.5 min.
The results showed that the four bioactive ﬂavonoids had highbinding afﬁnities in the physiological conditions. Equilibrium
dialysis may still be a suitable method for investigating simulta-
neously the binding characteristics (e.g., n and K) of several
compounds to plasma proteins.
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